These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
310 related articles for article (PubMed ID: 31365783)
1. Synthesis and Preliminary Evaluation of [ Chen Z; Shao T; Gao W; Fu H; Collier TL; Rong J; Deng X; Yu Q; Zhang X; Davenport AT; Daunais JB; Wey HY; Shao Y; Josephson L; Qiu WW; Liang S ChemMedChem; 2019 Sep; 14(17):1580-1585. PubMed ID: 31365783 [TBL] [Abstract][Full Text] [Related]
2. Development and biological evaluation of[ Malik N; Kornelsen R; McCormick S; Colpo N; Merkens H; Bendre S; Benard F; Sossi V; Schirrmacher R; Schaffer P Eur J Med Chem; 2021 Feb; 211():113005. PubMed ID: 33248850 [TBL] [Abstract][Full Text] [Related]
3. Preclinical Evaluation of Novel Positron Emission Tomography (PET) Probes for Imaging Leucine-Rich Repeat Kinase 2 (LRRK2). Chen Z; Chen J; Mori W; Yi Y; Rong J; Li Y; Leon ERC; Shao T; Song Z; Yamasaki T; Ishii H; Zhang Y; Kokufuta T; Hu K; Xie L; Josephson L; Van R; Shao Y; Factor S; Zhang MR; Liang SH J Med Chem; 2024 Feb; 67(4):2559-2569. PubMed ID: 38305157 [TBL] [Abstract][Full Text] [Related]
4. Synthesis and In Vitro and In Vivo Evaluation of [ Malik N; Gifford AN; Sandell J; Tuchman D; Ding YS Mol Imaging Biol; 2017 Dec; 19(6):837-845. PubMed ID: 28289968 [TBL] [Abstract][Full Text] [Related]
5. Chen X; Zhang Q; Zhang Y; Fang J; Jiang D; Mou Z; Liu H; Su R; Wang C; He F; Chen X; Xie F; Pan X; Li Z Eur J Med Chem; 2021 Mar; 214():113245. PubMed ID: 33582389 [No Abstract] [Full Text] [Related]
13. Leucine-Rich Repeat Kinase 2 in Parkinson's Disease: Updated from Pathogenesis to Potential Therapeutic Target. Chen J; Chen Y; Pu J Eur Neurol; 2018; 79(5-6):256-265. PubMed ID: 29705795 [TBL] [Abstract][Full Text] [Related]
14. Targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of Parkinson's disease. Domingos S; Duarte T; Saraiva L; Guedes RC; Moreira R Future Med Chem; 2019 Aug; 11(15):1953-1977. PubMed ID: 31517532 [TBL] [Abstract][Full Text] [Related]
15. Preclinical modeling of chronic inhibition of the Parkinson's disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo. Kluss JH; Mazza MC; Li Y; Manzoni C; Lewis PA; Cookson MR; Mamais A Mol Neurodegener; 2021 Mar; 16(1):17. PubMed ID: 33741046 [TBL] [Abstract][Full Text] [Related]
16. Effect of selective LRRK2 kinase inhibition on nonhuman primate lung. Fuji RN; Flagella M; Baca M; Baptista MA; Brodbeck J; Chan BK; Fiske BK; Honigberg L; Jubb AM; Katavolos P; Lee DW; Lewin-Koh SC; Lin T; Liu X; Liu S; Lyssikatos JP; O'Mahony J; Reichelt M; Roose-Girma M; Sheng Z; Sherer T; Smith A; Solon M; Sweeney ZK; Tarrant J; Urkowitz A; Warming S; Yaylaoglu M; Zhang S; Zhu H; Estrada AA; Watts RJ Sci Transl Med; 2015 Feb; 7(273):273ra15. PubMed ID: 25653221 [TBL] [Abstract][Full Text] [Related]
17. Characterization of the Onset, Progression, and Reversibility of Morphological Changes in Mouse Lung after Pharmacological Inhibition of Leucine-Rich Kinase 2 Kinase Activity. Bryce DK; Ware CM; Woodhouse JD; Ciaccio PJ; Ellis JM; Hegde LG; Kuruvilla S; Maddess ML; Markgraf CG; Otte KM; Poulet FM; Timmins LM; Kennedy ME; Fell MJ J Pharmacol Exp Ther; 2021 Apr; 377(1):11-19. PubMed ID: 33509901 [TBL] [Abstract][Full Text] [Related]